Latest data for managing ALK NSCLC patients

Bookmark and Share
This content is restricted to members who are registered with ecancer as a healthcare professional.
Please login or register for free to confirm your details.
Published: 11 Dec 2020
Views: 1602
Prof Myung-Ju Ahn - Samsung Medical Center, Seoul, South Korea

Prof Myung-Ju Ahn speaks to ecancer at the ESMO Asia Virtual Congress about the latest data for managing ALK NSCLC patients with a focus on Asian populations.

Much of the information regards a few recent large profile studies including J-ALTA and ALTA-1L , revealing the unmet needs, challenges, and treatment selection in first line (1L), 2L or 2L setting.

Prof Ahn then compares updated Asian vs non-Asian population data from the aforementioned studies and latest data from J-ALEX and ALESIA.

She rounds off by discussing the implications that the results from these 4 studies will have on clinical practise.

This programme has been supported by an unrestricted educational grant from Takeda.